Erasca, Inc. SEC Filings

Erasca, Inc. has filed a shelf registration providing flexibility to raise up to $500,000,000 of securities in one or more offerings, including common stock, preferred stock, debt securities, warrants and units. The filing also includes a sale-agreement prospectus for up to $200,000,000 of common stock that may be issued under an at-the-market Sale Agreement with Jefferies LLC; those shares are included in the $500,000,000 shelf amount. The prospectus states the companys common stock trades on Nasdaq under the symbol ERAS and reports a last sale price of $1.40 per share.

The document summarizes corporate governance and financing mechanics that matter to investors: authorized capital includes 800,000,000 common and 80,000,000 preferred shares; the board may issue undesignated preferred stock which could affect control and dilution; registration rights granted under a stockholders agreement terminate in August 2026. The prospectus also describes Erascas clinical-stage RAS/MAPK-focused pipeline, naming three clinical programs (naporafenib, ERAS-0015 and ERAS-4001) and a discovery program (ERAS-12), and directs investors to incorporated SEC reports for detailed financial and risk information.

Erasca reported total assets of $445.4 million and stockholders' equity of $372.3 million at June 30, 2025. The company held $386.7 million of combined cash, cash equivalents and marketable securities, and had an accumulated deficit of $832.5 million. The company states its cash and marketable securities are expected to fund operations for at least one year from issuance of these financial statements.

For the six months ended June 30, 2025 Erasca recorded a net loss of $64.8 million ($0.23 per share) and a net loss of $33.9 million for the quarter ended June 30, 2025 ($0.12 per share). Key program and corporate items disclosed include IND clearances in May 2025 for ERAS-0015 (AURORAS-1) and ERAS-4001 (BOREALIS-1), the in-license of naporafenib from Novartis, a strategic reprioritization to focus on naporafenib, ERAS-0015 and ERAS-4001, a $7.5 million IPR&D milestone expense related to the Joyo agreement in the period, and a subsequent Amended and Restated ATM agreement dated August 12, 2025 for up to $200 million.

Erasca, Inc. announced its financial results for the three months ended June 30, 2025 and furnished a press release containing the full results as Exhibit 99.1 to this Current Report. The filing notes the press release is being furnished rather than "filed," so it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings except by specific reference.

The Current Report identifies Exhibit 99.1 (press release) and a Cover Page Interactive Data File (104) as exhibits. No numerical financial data or consolidated financial statements are included in the text of this Form 8-K; readers are referred to the attached Exhibit 99.1 for the detailed results.

Erasca (Nasdaq: ERAS) filed a Form 8-K disclosing the 24 June 2025 annual meeting results. 241.8 million of 283.3 million entitled shares were represented (≈85%).

• Director elections: Jonathan Lim 196.99 M for / 2.19 M withheld; James Bristol 178.36 M for / 20.81 M withheld; Valerie Harding-Start 177.00 M for / 22.17 M withheld. All three Class I directors were elected for terms expiring in 2028.
• Auditor ratification: KPMG LLP received 240.25 M for, 1.27 M withheld, 0.31 M against; 0 broker non-votes.

No additional proposals were presented, and the filing notes no changes to governance, strategy, or capital structure.

Erasca, Inc. (ERAS) – Form 4 insider filing: Director Michael David Varney received a grant of 120,000 non-qualified stock options on 06/24/2025 at an exercise price of $1.45 per share. The options are subject to a one-year cliff; 100% vest on 06/24/2026, contingent on his continued service, and expire on 06/23/2035. No shares were purchased or sold; the transaction code “A” denotes an award. Following the grant, Varney beneficially owns 120,000 derivative securities, held directly. The filing does not list any other equity transactions or changes in common-stock ownership.

The option award aligns the director’s incentives with shareholder value creation, but also adds up to 120,000 potential new shares to the company’s fully diluted count once exercised.

SEC Form 4 snapshot for Erasca, Inc. (ERAS)

On June 26 2025, Director Jean I. Liu reported the receipt of a new equity award under Erasca’s incentive plan. The filing discloses 120,000 stock options (right to buy common shares) granted on June 24 2025 at an exercise price of $1.45 per share. All of the options vest in a single tranche on June 24 2026, provided Ms. Liu remains in continuous service, and they expire on June 23 2035.

• No non-derivative share transactions were reported; the disclosure relates solely to the derivative option grant.
• Following the grant, Ms. Liu shows beneficial ownership of 120,000 options, held directly.
• The transaction is coded “A” (grant without payment) and was executed outside a Rule 10b5-1 trading plan.

Option awards are routine director compensation meant to align governance incentives with shareholder value creation. The long-dated expiration (10 years) and one-year cliff vesting structure encourage strategic, long-term decision-making. The filing does not indicate any open-market buying or selling, nor does it alter Erasca’s capital structure. From an investment perspective, the event is informational rather than financially material, but it does confirm continued board engagement and standard equity-based retention practices.

Erasca, Inc. (ERAS) – Form 4 insider filing

Director Julie Hambleton received an option grant for 120,000 shares of common stock on 24 June 2025 at an exercise price of $1.45 per share. The option was issued at no cost, vests 100 % on 24 June 2026, and expires on 23 June 2035. Following the grant, Hambleton beneficially owns 120,000 derivative securities, held directly. No non-derivative share transactions were reported. The filing represents routine equity compensation for a board member and does not indicate immediate open-market buying or selling activity.

Key points from Erasca, Inc. (ERAS) Form 4

On 06/24/2025 the company granted Director Valerie Denise Harding a stock option for 120,000 common shares at an exercise price of $1.45. The transaction is coded “A” (acquisition) and is held directly by the director. According to the footnote, 100% of the option vests on 06/24/2026, provided the director remains in continuous service, and the option expires on 06/23/2035. After the grant the reporting person holds 120,000 derivative securities; no non-derivative share ownership or sales were reported.

No Rule 10b5-1 trading plan or other special conditions were indicated, and there were no accompanying purchases, sales, or exercises. The filing represents routine director compensation with limited immediate impact on Erasca’s capital structure or cash flow.